Angiology: Open Access
Open Access

Abstract

Dual Antiplatelet Therapy after Coronary Drug-eluting Stent Implantation in China: A Large Single Center Data

Jing-jing Xu#, Zhan Gao#, Ying Song, Xiao-fang Tang, Lin Jiang, Xue-yan Zhao, Yin Zhang, Li-jian Gao, Jue Chen, Shu-bin Qiao, Run-lin Gao, Yue-jin Yang, Bo Xu* and Jin-qing Yuan*

We investigated the real dual antiplatelet therapy (DAPT) duration after the drug-eluting stent (DES) treatment in China. 9,919 consecutive patients with DES implantation were enrolled. The follow-up DAPT cessation and associated factors with different DAPT durations were analyzed. The proportion of patients with DAPT coverage at 1-year follow-up was 97.3%, and decreased to 30.1% for 2-years. The distribution of DAPT duration (<1 year, =1 year and >1 year) was not significantly different among patients presented with AMI versus non-AMI (p=0.41), and new-generation DES versus first-generation DES (p=0.54). The multivariable analysis indicated some independent predictors of prolonging DAPT duration, including TVR (OR 2.50, 95% CI 2.04-3.06, p<0.001), stent numbers (OR 1.10, 95% CI 1.05-1.15, p<0.001), and previous coronary artery bypass grafting (OR 0.76, 95% CI 0.61-0.96, p=0.02). Other clinical factors such as the increased risks of bleeding and high ischemic risks were not associated with DAPT duration. 1-year DAPT after DES was applied to 97.3% in China. However, the DAPT duration after 1 year was not adjusted according to the patients’ bleeding situation and ischemic risks.